Novartis AG
NVS
$155.34
-$0.81-0.52%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.82% | 5.20% | 8.38% | 11.86% | 12.02% |
| Total Other Revenue | 0.21% | 44.30% | 52.46% | 49.52% | 46.35% |
| Total Revenue | 2.73% | 6.31% | 9.57% | 12.88% | 12.95% |
| Cost of Revenue | 8.38% | 6.88% | 6.33% | 10.96% | 9.53% |
| Gross Profit | 0.97% | 6.12% | 10.64% | 13.49% | 14.06% |
| SG&A Expenses | -0.19% | 4.20% | 5.38% | 6.59% | 5.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -11.91% | 55.50% | 65.83% | -123.76% | 9.44% |
| Total Operating Expenses | 6.64% | 9.59% | 8.79% | 11.85% | 8.21% |
| Operating Income | -4.92% | -0.32% | 11.28% | 14.86% | 23.53% |
| Income Before Tax | -0.55% | 5.81% | 19.88% | 28.96% | 43.21% |
| Income Tax Expenses | 40.86% | 10.30% | 40.21% | 108.82% | 142.01% |
| Earnings from Continuing Operations | -6.53% | 5.09% | 16.99% | 22.34% | 35.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -37.50% | 2,100.00% | 750.00% | 150.00% | 900.00% |
| Net Income | -6.57% | 5.25% | 17.11% | -18.24% | -15.59% |
| EBIT | -4.92% | -0.32% | 11.28% | 14.86% | 23.53% |
| EBITDA | -3.29% | 0.50% | 9.52% | 12.52% | 17.57% |
| EPS Basic | -3.54% | 9.24% | 21.82% | -14.70% | -12.56% |
| Normalized Basic EPS | -5.51% | -0.37% | 12.43% | 18.73% | 27.65% |
| EPS Diluted | -3.40% | 9.18% | 21.54% | -14.76% | -12.68% |
| Normalized Diluted EPS | -5.42% | -0.30% | 12.49% | 18.71% | 27.61% |
| Average Basic Shares Outstanding | -3.31% | -3.80% | -3.97% | -3.81% | -3.35% |
| Average Diluted Shares Outstanding | -3.40% | -3.86% | -4.00% | -3.80% | -3.30% |
| Dividend Per Share | 20.81% | 20.81% | 20.81% | -1.44% | -1.44% |
| Payout Ratio | 0.24% | 0.06% | -0.12% | 0.25% | 0.21% |